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Information on comorbidities and medication of people with dementia (PWD) in long-
term-facilities (LTF) is scarce. This study analysed type and number of comorbidities and
medication of PWD in LTF. A descriptive-study was conducted in 40 LTF, characterising
329  PWD.  Socio-demographics, dementia type, comorbidities and medication were col-
lected with International-Classiﬁcation-of-Functionality-checklist. Cognitive impairment
was  assessed with Mini-Mental-State-Examination. One or more comorbidities (2.1 ± 1.6)
were  found in 271 participants. Hypertension, osteoarticular-problems, heart-disease and
type-II-diabetes were the frequently comorbidities. 327 participants consumed one or more
medicines (7.3 ± 3.2), mainly for cardiovascular system, anxiolytics and antipsychotics.
Comorbidities and medication amount was signiﬁcantly different among cognitive impair-
ment levels. Vascular comorbidities were present in all dementia types.
©  2014 The Authors. Published by Elsevier España, S.L.U. on behalf of Escola Nacional de
Saúde Pública. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/4.0/).
Comorbilidades  e  medicac¸ão  em  pessoas  com  demência  em  lares  de
idosos
r  e  s  u  m  oPalavras-chave:
Pessoas com demência
Comorbilidades
Medicac¸ão
Lares de idosos
O conhecimento acerca das comorbilidades e da medicac¸ão em pessoas com demência
(PCD) que vivem em lares de idosos é limitado. Assim, este estudo analisou o tipo e número
de  comorbilidades e medicac¸ão de PCD que vivem em lares de idosos portugueses. Um
estudo descritivo foi conduzido em 40 em lares de idosos. Foram incluídas 329 pessoas com
diagnóstico de demência, das quais foram recolhidas informac¸ões sociodemográﬁcas, das
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comorbilidades e medicac¸ão com a checklist da Classiﬁcac¸ão Internacional de Funcional-
idade. O déﬁce cognitivo foi avaliado através do Mini-Mental State Examination. Uma ou
mais  comorbilidades (2,1 ± 1,6) foi encontrada em 271 participantes. Hipertensão, prob-
lemas osteoarticulares, doenc¸a cardíaca e diabetes tipo II foram as comorbilidades mais
frequentes. 327 participantes consumiam um ou mais medicamentos (7,3 ± 3,2), principa-
mente medicac¸ão para o sistema cardiovascular, ansiolíticos e anti-psicóticos. A quantidade
de  comorbilidades e medicac¸ão foi signiﬁcativamente diferente entre os níveis de déﬁce
cognitivo. Comorbilidades vasculares estavam presentes em todos os tipos de demência.
©  2014 The Authors. Publicado por Elsevier España, S.L.U. em nome da Escola Nacional
de  Saúde Pública. Este é um artigo Open Access sob a licença de CC BY-NC-SA
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less (n = 4) and/or severe hearing impaired (n = 2); (iii) have not
been at the care facility for at least 3 months (n = 6); (v) or diedntroduction
ementia is a global health challenge.1 In the year 2010 it was
stimated that 35.6 million people had Alzheimer’s disease
nd other dementias worldwide.2 This number will increase
ith an ageing world population and will reach 66 million by
he year 2030 and 115 million by 2050.1
Comorbidities are highly prevalent among people with
ementia3 and have been reported as risk factors for cognitive
mpairment and dementia progression. A study associated
omorbidities to half of the Alzheimer’s disease cases world-
ide and it has been suggested that the reduction of 10–25%
n these factors could prevent 3 million cases of Alzheimer’s
isease worldwide.4 Consequently, comorbidities contributes
o dementia onset4 and may also lead to faster progression
f the disease, representing an additional factor for disability
nd increased costs.5 However, the levels of comorbidities in
eople with dementia remain a controversial issue, with some
tudies reporting that this population present fewer than non-
emented people6,7 and others suggesting more  comorbidities
han generally thought.8,9 This controversy causes difﬁculties
hen appropriate measures to prevent and treat comorbidi-
ies in dementia have to be deﬁned.10 Additionally, high levels
f comorbidities have been linked with high amount of pre-
cribed medication in people with dementia when compared
ith other individuals.11 The use of psychotropic medication
antipsychotics, antidepressants and anxiolytics) in people
ith dementia has been studied.11 However, this medication,
onsumed specially by people living in long-term care facil-
ties, showed to be inappropriate and has been associated
ith numerous adverse events, which led to hospitalisation
nd higher mortality.11 Nevertheless, the overall medication
escription in people with dementia living in long-term care
acilities10,12 is still unknown, as this population due to their
ognitive impairment tend to be excluded from the studies. In
 time in which reducing costs and optimising health care is
rucial,2 characterising comorbidities and medication intake
f people with dementia becomes crucial, as this information
as the potential to inform decision on appropriate strategies
o prevent and treat comorbidities, adjust medication and sup-
ort planning of health and social resources.13 Therefore, this
tudy aimed to analyse the type and number of comorbidities
nd medication of people with dementia living in long-term
are facilities.(http://creativecommons.org/licenses/by-nc-sa/4.0/).
Methods
Study  design
An exploratory descriptive study was conducted in the cen-
tral region of Portugal. The study was submitted to the Ethics
Committee of the Research Unit of Health Sciences at the
Health School of Nursing in Coimbra (UICISA: E), Portugal
(Ref. 5-11/2010) and approval was obtained. Legal represent-
atives were invited to attend a meeting where verbal and
written information about the study was provided. A brief
explanation about the study was also given to people with
dementia. Written informed consents were collected from
the legal representatives of the people with dementia living
in the long-term care facilities prior to any data collec-
tion.
Participants
Fifty-seven long-term care facilities were contacted and infor-
mation about the study was provided to the service managers
in an arranged meeting. Forty care facilities with a total
of 1780 residents accepted to participate. Participants were
included in the study if they presented a medical diagno-
sis of irreversible dementia according to the Diagnostic and
Statistical Manual of Mental Disorders IV (DSM-IV) criteria.14
People with dementia were excluded if: (i) refused to answer
to the Mini-Mental State Examination (MMSE); (ii) were severe
or total sightless and/or severe hearing impaired; (iii) had not
been at the care facility for at least 3 months (considered the
minimum individual time needed to adjust to the institution
dynamics); (iv) did not have a legal representative to sign the
written informed consent; (v) or died during the data collec-
tion.
From the total individuals living in the long-term care
facilities, 353 (19.8%) had a medical diagnosis of dementia.
However, 24 subjects were excluded as they: (i) refused to
answer to the MMSE (n = 4) or their family did not sign the
written informed consent (n = 2); (ii) were severe or total sight-during the data collection (n = 10). Thus, a total of 329 people
with dementia were included.
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Table 1 – Sample characteristics (n = 329).
Variables n %
Age (years)
50–64 3 0.9
65–74 32 9.7
75–84 136 41.3
+85 158 48.0
Gender
Male 67 20.4
Female 262 79.6
Years of education
Illiterate 97 29.5
1–4 168 51.1
5–9 17 5.1
+10 20 6.1
Missing 27 8.2
Marital status
Single 53 16.1
Married/Living with a partner 61 18.5
Divorced/Separated 15 4.6
Widowed 200 60.8
Time living in the long-term care facility (years)
<1 105 31.9
2–4 119 36.2
5–7 54 16.4
8–10 27 8.2
>11 24 7.3
Types of dementia
Unspeciﬁed dementia 148 45.0
Alzheimer Disease 138 41.9
Vascular Dementia 29 8.8
Other types 14 4.3
Severity of the cognitive impairment (MMSE score)
Mild cognitive impairment (21–27) 28 8.5
Moderate cognitive impairment (11–20) 95 28.9
Severe cognitive impairment (0–10) 203 61.744  r e v p o r t s a ú d e p ú
Measures
A structured questionnaire based on the International Classiﬁ-
cation of Functionality, Disability and Health (ICF) checklist15
was used to collect data about socio-demographics, type of
dementia, type and number of comorbidities and medication
of people with dementia. This is a checklist of major categories
of the International Classiﬁcation of Functioning, Disability
and Health (ICF) of the World Health Organization. It is a prac-
tical tool to record health information of each individual and
across different populations. This information was obtained
from clinical ﬁles and staff (health professionals, service man-
agers, direct care providers).
The MMSE  adapted to the Portuguese population16 was
applied to the people with dementia to assess their cognitive
status. The severity of the cognitive impairment was char-
acterised using the MMSE  cut-offs, published in European
studies, i.e., 21–27 mild, 11–20 moderate and 0–10 severe.
Data  analyses
Data analysis was performed using the PASW Statistics ver-
sion 18.0 for Windows (SPSS Inc., Chicago, IL). Descriptive
statistics were applied to characterise the sample. Non para-
metric tests were performed as variables did not follow a
normal distribution and the sample size was lower than
30 subjects in some variables sub-groups.17 Therefore, the
Mann–Whitney and Kruskal–Wallis non-parametric tests were
applied to explore the differences between the number of
comorbidities and the sample characteristics (age, education,
marital status, period living in the long-term care facility, type
of dementia and severity of cognitive impairment); and the
amount of medication used and the sample characteristics.
The correlation between the number of comorbidities and the
amount of medication used was analysed with the Pearson
coefﬁcient (r), as the sample size was higher than 30 subjects.17
A -value less than 0.05 was considered statistically signiﬁ-
cant.
Results
Sample  characteristics
Table 1 describes the sample characteristics. People with
dementia mean age was 83.6 ± 7.1 years old. Most were older
than 85 years old (n = 158; 48%), female (n = 262; 79.6%), had
one to four years of education (n = 168; 51.1%) or no educa-
tion (n = 97; 29.5%), were widowed (n = 200; 60.8%) and were
living in the facility for less than 1 year (n = 105; 31.9%) or from
2 to 4 years (n = 119; 36.2%). Most participants did not have
their type of dementia deﬁned (n = 148; 45%) however, from the
participants who  presented a speciﬁc diagnosis, Alzheimer’s
disease was the most prevalent (n = 138; 41.9%). According to
the MMSE, an average score of 8.7 ± 7.9 was found and 61.7%
(n = 203) had severe cognitive impairment (Table 1).Comorbidities
One or more  comorbidities (2.1 ± 1.6) were found in 271 (82.4%)
participants (Table 2). The most frequent comorbidities wereNot applicable 3 0.9
hypertension (n = 136; 41.3%), osteoarticular problems (n = 73;
22.2%), heart disease (n = 67; 20.4%), type II diabetes (n = 65;
19.8%) and hypercholesterolemia (n = 42; 12.8%) (Table 2).
Most participants with unspeciﬁed dementia (n = 67) and
Alzheimer’s disease (n = 71) had 1–2 comorbidities, whilst
subjects with vascular dementia (n = 12) had 3–4 comorbidi-
ties (Table 3). Vascular risk factors were the most frequent
among participants however, they were more  prevalent in
people with vascular dementia (hypertension – 68.9%, heart
disease – 44.8%, type II diabetes – 37.9% and hypercholes-
terolemia – 24.1%) than in people with unspeciﬁed dementia
(hypertension – 40.5%, heart disease – 22.9%, type II dia-
betes – 17.2% and hypercholesterolemia – 12.2%) or Alzheimer
disease participants (hypertension – 35.8%, heart disease –
13.4%, type II diabetes – 17.2% and hypercholesterolemia –
10.4%).
The number of comorbidities was not signiﬁcantly differ-
ent according to age or gender however, it was signiﬁcantly
different among the types of dementia ( < 0.001) and severity
( = 0.005) of cognitive impairment (Table 3), in which indi-
viduals with severe cognitive impairment presented a higher
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Table 2 – Description of people with dementia
comorbidities (n = 329).
n %
Types of comorbidities
Hypertension 136 41.3
Osteoarticular problems 73 22.2
Heart disease 67 20.4
Type II diabetes 65 19.8
Hypercholesterolemia 42 12.8
Gastro-intestinal problems 33 10.0
Depression 32 9.7
Parkinson disease 27 8.2
Renal problems 26 7.9
Vascular and circulatory problems 25 7.6
Visual problems 24 7.3
Respiratory problems 21 6.4
Anaemia 17 5.2
Osteoporosis 15 4.6
Hearing problems 13 4.0
Neoplasms 13 4.0
Genitourinary problems 10 3.0
Thyroid hormone problems 8 2.4
Missing 4 1.2
Number of comorbidities
0 58 17.6
1–2 151 45.9
a
c
w
b3–4 93 28.3
+5 27 8.2
mount of comorbidities than those with mild to moderate
ognitive impairment. However, 14.0% (n = 46) of the sample
ith severe cognitive impairment also presented no comor-
idities (Table 3).
Table 3 – Differences in the number of comorbidities and medic
and severity of cognitive impairment (n = 329).
Number of comorbidities 
n M [IQR] 
Age
50–64 3 2 [1;2] 
65–74 32 2 [2;3] 
75–84 136 2 [2;3] 
+85 158 2 [2;3] 
Gender
Male 67 2 [2;3] 
Female 262 2 [2;3] 
Type of dementia
Unspeciﬁed 148 2 [2;3] 
Alzheimer disease 138 2 [1;2] 
Vascular dementia 29 3 [2;3] 
Other types 14 3 [2;3] <
Severity (MMSE)
Mild 31 2 [2;3] 
Moderate 95 2 [2;3] 
Severe 203 2 [2;3] 
M: median; IQR: interquartile range [p25; p75]; : -value.
In bold statistically signiﬁcant p-values.
a Kruskal–Wallis.
b Mann–Whitney. . 2 0 1 5;3  3(1):42–48 45
Medication  intake
One or more  medicines (7.3 ± 3.2) were consumed by 327
(99.4%) participants (Table 4). Medication for the cardiovas-
cular system (n = 238; 72.3%), anxiolytics (n = 178; 54.1%) and
antipsychotics (n = 176; 53.5%) were the most commonly used
(Table 4).
There were no statistically signiﬁcant differences between
the amount of medication used and age, gender and type of
dementia (Table 3). The amount of medication was signif-
icantly different among the levels of cognitive impairment
( < 0.001) (Table 3) i.e., a higher amount of medication was
observed in people with severe cognitive impairment.
Number  of  comorbidities  vs.  amount  of  medication
There was a signiﬁcant positive correlation of 0.39 ( < 0.001)
between the number of comorbidities and the amount of med-
ication used by people with dementia living in long-term care
facilities.
Discussion
Similarly to others, this study found a high number of comor-
bidities in people with dementia living in long-term care
facilities, speciﬁcally hypertension,18 heart disease,10 type II
diabetes19 and hypercholesterolemia.18 These comorbidities,
which represent vascular risk factors, have been referred as
highly prevalent in numerous populations with dementia8,20
and have been associated with an increased risk of devel-
oping dementia.21 Evidence4,22 suggests that preventing and
ation according to age, gender, type of dementia
Number of medications
 n M [IQR] 
3 2 [2;2]
29 3 [2;3]
115 3 [3;3]
0.223a 137 3 [2;3] 0.221a
67 3 [2;3]
0.605b 262 3 [2;3] 0.213b
148 3 [2;3]
138 3 [2;3]
29 3 [2;3]
0.001a 14 3 [3;3] 0.487a
31 3 [2;3]
95 3 [3;3]
0.005a 203 3 [3;4] <0.001a
46  r e v p o r t s a ú d e p ú b l i c
Table 4 – Description of people with dementia
medication (n = 329).
n %
Type of medication
Cardiovascular system 238 72.3
Anxiolytic sedatives and hypnotics 178 54.1
Antipsychotic 176 53.5
Treatment of cognitive changes 151 45.9
Antidepressants 144 43.8
Gastrointestinal system 122 37.1
Anticoagulants 118 35.9
Analgesics and antipyretics 90 27.4
Cholesterol inhibitors 82 24.9
Anti-diabetics and insulin 66 20.1
Antiparkinsonian agents 64 19.5
Antianemics 63 19.1
Muscle-skeletal system 55 16.7
Antiepileptic and anticonvulsant 52 15.8
Genital-urinary system 35 10.6
Respiratory system 30 9.1
Eye system 22 6.7
Number of medications
0 2 0.6
1–5 91 27.7
6–10 188 57.1
A large amount of medication in people with dementia was11–15 45 13.7
+16 3 0.9
treating vascular risks factors could prevent or delay the incre-
ment of cognitive impairment in people without dementia
and reduce the burden associated with vascular risk factors
on those with dementia. Therefore, as no cure is available
for dementia, primary prevention of comorbidities, seems to
have great potential to reduce the number of dementia cases
emerging each year4 however, this needs further investigation.
Although the number of comorbidities was not signiﬁ-
cantly different considering age and gender,8 people with
more  severe cognitive impairment had a higher number of
comorbidities. Moreover, the absence of comorbidities in sev-
eral individuals with severe cognitive impairment, found in
this study, suggests a possible lack of diagnosis.23,24 This
means that if the comorbidities diagnosis is not performed
in mild to moderate stages, it might be difﬁcult to be made
in the severe stages of the disease, since this population does
not complain or receive frequent clinical revision.23
Furthermore, the amount of comorbidities was signiﬁ-
cantly different according to type of dementia. Therefore,
vascular dementia was associated with a higher number
of comorbidities than unspeciﬁed dementia or Alzheimer’s
disease.8,25 This type of dementia had shown a higher preva-
lence of vascular risk factors, such as hypertension, heart
disease, type II diabetes and hypercholesterolemia. Although
Alzheimer’s disease and vascular dementia shared several
risk factors, hypotheses have been raised suggesting that the
increase burden associated with vascular risk factors or with
the number of vascular diseases lead to an increased risk of
vascular dementia,26 explaining the ﬁndings of this study.
The average number of medication prescribed to peo-
ple with dementia living in long-term care facilities was
7.3 ± 3.2, higher than the average found in other research
studies which ranged between 5.1 and 6.53,27,28 however, a . 2 0 1 5;3 3(1):42–48
similar to the study of Andersen et al.,10 that reported a
mean of 6.9 ± 3.9 medicines. The medication used in dementia
has been associated with several side effects, e.g., deteriora-
tion of cognitive and psychomotor function, sedation, falls,
fractures,29 increased risk of delirium,11 increased risk of
stroke and dying.30 Therefore, the adequacy of the medica-
tion in people with dementia should be explored for each
person before decisions are taken 30 since it appropriate
use has already been questioned,10–12 mainly in long-term
care facilities.31 Furthermore, non-pharmacological interven-
tions seem a promising approach to reduce these type of
medication32 and merits further research.
Previous studies reported that people with more
severe cognitive impairment consume a higher amount
of medication,10,33 which is in agreement with the results
of this study. Questions on the potential overuse and cost-
effectiveness of medication in people with dementia should
be assessed in all stages of dementia and mainly on severe
dementia, in which decisions to discontinue some medica-
tion should be explored, e.g., antipsychotics interruption if
symptoms have been absent or minimal for three months.12
The signiﬁcant positive correlation found between the
number of comorbidities and the amount of medication pre-
scribed in people with dementia was previously reported
by Linjakumpu et al.,34 and highlights the importance of
preventing and treating comorbidities to reduce the use of
medication in this population. A lower number of comor-
bidities and consequently amount of medication would
potentially result in the reduction of cognitive and functional
decline, lower risk of institutionalisation, hospitalisation3 and
mortality and therefore, merits further research.
Clinical  implications
• High levels of comorbidities (i.e., hypertension, osteoar-
ticular problems, heart disease, type II diabetes and
hypercholesterolemia) were found in people with demen-
tia living in long-term care facilities. The supervision and
earlier treatment of these comorbidities might reduce mor-
bidity and improve quality of life of people with dementia.
• A large amount of medication was consumed by people with
dementia in all stages of the disease, mainly medication for
the cardiovascular system, anxiolytics and antipsychotics.
• Vascular dementia was associated with a higher number
of comorbidities than unspeciﬁed dementia or Alzheimer’s
disease. Treating vascular risk factors might be important
to reduce the risk of vascular dementia.
Conclusion
The high number of comorbidities found, mainly vascular risk
factors for dementia onset and progression, raises awareness
for the potential prevention of dementia cases through early
diagnosis and treatment of vascular risk factors and comor-
bidities.also found, when compared with previous studies. This study
alerts for the possibility of inappropriate use of medication
in people with dementia living in long-term care facilities.
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dditionally, as the number of comorbidities was linked with
he amount of medication, the prevention and treatment of
omorbidities could result in a lower amount of medication
ntake.
The design of this study was suitable to perform a descrip-
ive analysis on comorbidities and medication intake of
ortuguese people with dementia living in log-term care facil-
ties. However, comparisons across studies using different
ethodologies impair the generalisation of results. Future
esearch should be conducted with more  robust designs,
ncluding a control group of people with dementia living in the
ommunity should be conducted to strengthen these ﬁndings
nd explore differences thoroughly.
Since a cure for dementia is not available yet, ﬁnding effec-
ive approaches to reduce the burden associated with the
isease, improve people’s quality of life and reduce the dis-
ase associated costs are essential for a sustainable society in
n aging world.
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